423142-30-7Relevant articles and documents
Novel symmetrical cage compounds as inhibitors of the symmetrical mrp4-efflux pump for anticancer therapy
Kreutzer, David,D?ring, Henry,Werner, Peter,Ritter, Christoph A.,Hilgeroth, Andreas
, (2021/05/13)
Within the last decades cancer treatment improved by the availability of more specifically acting drugs that address molecular target structures in cancer cells. However, those target-sensitive drugs suffer from ongoing resistances resulting from mutation
Novel non-substrate modulators of the transmembrane efflux pump P-glycoprotein (ABCB1)
Krawczyk, S?ren,Baumert, Christiane,Molnár, Joséf,Ritter, Christoph,H?pner, Jens,Kloft, Charlotte,Hilgeroth, Andreas
supporting information, p. 860 - 866 (2015/05/27)
Novel N- and 4-substituted 1,4-dihydropyridines with a C2-symmetric molecular scaffold have been profiled as highly active modulators of the transmembrane efflux pump P-glycoprotein (P-gp, ABCB1) in an exclusively P-gp overexpressing cell line